IRAK4 as a molecular target in the amelioration of innate immunity-related endotoxic shock and acute liver injury by chlorogenic acid

Journal of Immunology

Volumn 194, Issue 3, 2015, Pages 1122-1130

  Park, Sun Hong ^a   Baek, Seung Il ^a   Yun, Jieun ^b   Lee, Seungmin ^a   Yoon, Da Young ^a   Jung, Jae Kyung ^a   Jung, Sang Hun ^c   Hwang, Bang Yeon ^a   Hong, Jin Tae ^a   Kim, Youngsoo ^a  

^a Chungbuk National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CHLOROGENIC ACID; CHLOROGENIC ACID JK001; GALACTOSAMINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; JANUS KINASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PLANT MEDICINAL PRODUCT; RESATORVID; SILYMARIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CYTOKINE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, MOUSE; IRAK4 PROTEIN, MOUSE;

ACUTE LIVER INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; C57BL 6 MOUSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIVER INJURY; MOLECULAR DYNAMICS; MORTALITY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; SEPTIC SHOCK; SURVIVAL RATE; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LIVER; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TOXIC HEPATITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHLOROGENIC ACID; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; IMMUNITY, INNATE; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LIPOPOLYSACCHARIDES; LIVER; MICE; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 84921491563     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402101     Document Type: Article

References (36)

1. Kenny, E. F., and L. A. O'Neill. 2008. Signalling adaptors used by Toll-like receptors: an update. Cytokine 43: 342-349.
2. Yamamoto, M., and S. Akira. 2010. Lipid A receptor TLR4-mediated signaling pathways. Adv. Exp. Med. Biol. 667: 59-68.
3. Lu, Y. C., W. C. Yeh, and P. S. Ohashi. 2008. LPS/TLR4 signal transduction pathway. Cytokine 42: 145-151.
4. Flannery, S., and A. G. Bowie. 2010. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem. Pharmacol. 80: 1981-1991.
5. Landström, M. 2010. The TAK1-TRAF6 signalling pathway. Int. J. Biochem. Cell Biol. 42: 585-589.
6. Dai, L., C. Aye Thu, X. Y. Liu, J. Xi, and P. C. Cheung. 2012. TAK1, more than just innate immunity. IUBMB Life 64: 825-834.
7. Tornatore, L., A. K. Thotakura, J. Bennett, M. Moretti, and G. Franzoso. 2012. The nuclear factor k B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol. 22: 557-566.
8. Newton, K., and V. M. Dixit. 2012. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 4: a006049.
9. Hoesel, B., and J. A. Schmid. 2013. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 12. Available at: http://www.molecular-cancer.com/content/12/1/86.
10. Napetschnig, J., and H. Wu. 2013. Molecular basis of NF-κB signaling. Annu Rev Biophys 42: 443-468.
11. Perales-Linares, R., and S. Navas-Martin. 2013. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology 140: 153-167.
12. Hyun, J., S. Kanagavelu, and M. Fukata. 2013. A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses. Microbes Infect. 15: 1-10.
13. Opal, S. M., P. F. Laterre, B. Francois, S. P. LaRosa, D. C. Angus, J. P. Mira, X. Wittebole, T. Dugernier, D. Perrotin, M. Tidswell, et al; ACCESS Study Group. 2013. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309: 1154-1162.
14. Rice, T. W., A. P. Wheeler, G. R. Bernard, J. L. Vincent, D. C. Angus, N. Aikawa, I. Demeyer, S. Sainati, N. Amlot, C. Cao, et al. 2010. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38: 1685-1694.
15. Mullarkey, M., J. R. Rose, J. Bristol, T. Kawata, A. Kimura, S. Kobayashi, M. Przetak, J. Chow, F. Gusovsky, W. J. Christ, and D. P. Rossignol. 2003. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304: 1093-1102.
16. Takashima, K., N. Matsunaga, M. Yoshimatsu, K. Hazeki, T. Kaisho, M. Uekata, O. Hazeki, S. Akira, Y. Iizawa, and M. Ii. 2009. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br. J. Pharmacol. 157: 1250-1262.
17. Tse, M. T. 2013. Trial watch: Sepsis study failure highlights need for trial design rethink. Nat. Rev. Drug Discov. 12: 334.
18. Zanotti-Cavazzoni, S. L., and R. D. Goldfarb. 2009. Animal models of sepsis. Crit. Care Clin. 25: 703-719, vii-viii.
19. Doi, K., A. Leelahavanichkul, P. S. Yuen, and R. A. Star. 2009. Animal models of sepsis and sepsis-induced kidney injury. J. Clin. Invest. 119: 2868-2878.
20. Lee, C. H., S. J. Yoon, and S. M. Lee. 2012. Chlorogenic acid attenuates high mobility group box 1 (HMGB1) and enhances host defense mechanisms in murine sepsis. Mol. Med. 18: 1437-1448.
21. Park, S. H., E. Roh, H. S. Kim, S. I. Baek, N. S. Choi, N. Kim, B. Y. Hwang, S. B. Han, and Y. Kim. 2013. Inhibition of IRAK-4 activity for rescuing endotoxin LPS-induced septic mortality in mice by lonicerae flos extract. Biochem. Biophys. Res. Commun. 442: 183-188.
22. Xu, Y., J. Chen, X. Yu, W. Tao, F. Jiang, Z. Yin, and C. Liu. 2010. Protective effects of chlorogenic acid on acute hepatotoxicity induced by lipopolysaccharide in mice. Inflamm. Res. 59: 871-877.
23. Wu, Z., M. Han, T. Chen, W. Yan, and Q. Ning. 2010. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int. 30: 782-794.
24. Buss, H., A. Dörrie, M. L. Schmitz, E. Hoffmann, K. Resch, and M. Kracht. 2004. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-κB at serine 536 is mediated by multiple protein kinases including IkB kinase (IKK)-α, IKKβ, IKKε, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J. Biol. Chem. 279: 55633-55643.
25. Chen, W., H. Srinath, S. S. Lam, C. A. Schiffer, W. E. Royer, Jr., and K. Lin. 2008. Contribution of Ser386 and Ser396 to activation of interferon regulatory factor 3. J. Mol. Biol. 379: 251-260.
26. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
27. Qureshi, S. T., L. Larivière, G. Leveque, S. Clermont, K. J. Moore, P. Gros, and D. Malo. 1999. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189: 615-625.
28. Fraczek, J., T. W. Kim, H. Xiao, J. Yao, Q. Wen, Y. Li, J. L. Casanova, J. Pryjma, and X. Li. 2008. The kinase activity of IL-1 receptor-associated kinase 4 is required for interleukin-1 receptor/toll-like receptor-induced TAK1-dependent NFkappaB activation. J. Biol. Chem. 283: 31697-31705.
29. Hashimoto, S., K. Morohoshi, T. Suzuki, and K. Matsushima. 2003. Lipopolysaccharide-inducible gene expression profile in human monocytes. Scand. J. Infect. Dis. 35: 619-627.
30. Suzuki, N., S. Suzuki, G. S. Duncan, D. G. Millar, T. Wada, C. Mirtsos, H. Takada, A. Wakeham, A. Itie, S. Li, et al. 2002. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416: 750-756.
31. Kawagoe, T., S. Sato, A. Jung, M. Yamamoto, K. Matsui, H. Kato, S. Uematsu, O. Takeuchi, and S. Akira. 2007. Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J. Exp. Med. 204: 1013-1024.
32. Swantek, J. L., M. F. Tsen, M. H. Cobb, and J. A. Thomas. 2000. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J. Immunol. 164: 4301-4306.
33. Thomas, J. A., J. L. Allen, M. Tsen, T. Dubnicoff, J. Danao, X. C. Liao, Z. Cao, and S. A. Wasserman. 1999. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J. Immunol. 163: 978-984.
34. Zhang, X., H. Huang, T. Yang, Y. Ye, J. Shan, Z. Yin, and L. Luo. 2010. Chlorogenic acid protects mice against lipopolysaccharide-induced acute lung injury. Injury 41: 746-752.
35. Shi, H., L. Dong, J. Jiang, J. Zhao, G. Zhao, X. Dang, X. Lu, and M. Jia. 2013. Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway. Toxicology 303: 107-114.
36. Chauhan, P. S., N. K. Satti, P. Sharma, V. K. Sharma, K. A. Suri, and S. Bani. 2012. Differential effects of chlorogenic acid on various immunological parameters relevant to rheumatoid arthritis. Phytother. Res. 26: 1156-1165.